Burdick, K. E., Millett, C. E., Russo, M., Alda, M., Alliey-Rodriguez, N., Anand, A., Balaraman, Y., Berrettini, W., Bertram, H., Calabrese, J. R., Calkin, C., Conroy, C., Coryell, W., DeModena, A., Feeder, S., Fisher, C., Frazier, N., Frye, M., Gao, K., ... Kelsoe, J. R. (2020). The association between lithium use and neurocognitive performance in patients with bipolar disorder. Neuropsychopharmacology, 45(10), 1743-1749. https://doi.org/10.1038/s41386-020-0683-2
Burdick, KE, Millett, CE, Russo, M, Alda, M, Alliey-Rodriguez, N, Anand, A, Balaraman, Y, Berrettini, W, Bertram, H, Calabrese, JR, Calkin, C, Conroy, C, Coryell, W, DeModena, A, Feeder, S, Fisher, C, Frazier, N, Frye, M, Gao, K, Garnham, J, Gershon, ES, Glazer, K, Goes, FS, Goto, T, Harrington, GJ, Jakobsen, P, Kamali, M, Kelly, M, Leckband, S, Løberg, EM, Lohoff, FW, Maihofer, AX, McCarthy, MJ, McInnis, M, Morken, G, Nievergelt, CM, Nurnberger, J, Oedegaard, KJ, Ortiz, A, Ritchey, M, Ryan, K, Schinagle, M, Schwebel, C, Shaw, M, Shilling, P, Slaney, C, Stapp, E, Tarwater, B, Zandi, P & Kelsoe, JR 2020, 'The association between lithium use and neurocognitive performance in patients with bipolar disorder', Neuropsychopharmacology, vol. 45, no. 10, pp. 1743-1749. https://doi.org/10.1038/s41386-020-0683-2
@article{abeb8fa5abd84a6aa0ad11314c33acdb,
title = "The association between lithium use and neurocognitive performance in patients with bipolar disorder",
abstract = "Lithium remains the gold standard for the treatment of bipolar disorder (BD); however, its use has declined over the years mainly due to the side effects and the subjective experience of cognitive numbness reported by patients. In the present study, we aim to methodically test the effects of lithium on neurocognitive functioning in the largest single cohort (n = 262) of BD patients reported to date by harnessing the power of a multi-site, ongoing clinical trial of lithium monotherapy. At the cross-sectional level, multivariate analysis of covariance (MANCOVA) was conducted to examine potential group differences across neurocognitive tests [California Verbal Learning Test (CVLT trials 1–5,CVLT delayed recall), Wechsler Digit Symbol, Trail-making Test parts A and B (TMT-A; TMT-B), and a global cognition index]. At the longitudinal level, on a subset of patients (n = 88) who achieved mood stabilization with lithium monotherapy, we explored the effect of lithium treatment across time on neurocognitive functioning. There were no differences at baseline between BD patients that were taking lithium compared with those that were not. At follow-up a significant neurocognitive improvement in the global cognitive index score [F = 31.69; p < 0.001], CVLT trials 1–5 [F = 29.81; p < 0.001], CVLT delayed recall [F = 15.27; p < 0.001], and TMT-B [F = 6.64, p = 0.012] was detected. The cross-sectional and longitudinal (on a subset of 88 patients) investigations suggest that lithium may be beneficial to neurocognitive functioning in patients with BD and that at the very least it does not seem to significantly impair cognition when used therapeutically.",
author = "Burdick, {Katherine E.} and Millett, {Caitlin E.} and Manuela Russo and Martin Alda and Ney Alliey-Rodriguez and Amit Anand and Yokesh Balaraman and Wade Berrettini and Holli Bertram and Calabrese, {Joseph R.} and Cynthia Calkin and Carla Conroy and William Coryell and Anna DeModena and Scott Feeder and Carrie Fisher and Nicole Frazier and Mark Frye and Keming Gao and Julie Garnham and Gershon, {Elliot S.} and Kara Glazer and Goes, {Fernando S.} and Toyomi Goto and Harrington, {Gloria J.} and Petter Jakobsen and Masoud Kamali and Marisa Kelly and Susan Leckband and L{\o}berg, {Else Marie} and Lohoff, {Falk W.} and Maihofer, {Adam X.} and McCarthy, {Michael J.} and Melvin McInnis and Gunnar Morken and Nievergelt, {Caroline M.} and John Nurnberger and Oedegaard, {Ketil J.} and Abigail Ortiz and Megan Ritchey and Kelly Ryan and Martha Schinagle and Candice Schwebel and Martha Shaw and Paul Shilling and Claire Slaney and Emma Stapp and Bruce Tarwater and Peter Zandi and Kelsoe, {John R.}",
note = "Funding Information: This work was supported by the US National Institutes of Mental Health and General Medical Sciences (MH92758 to JRK; MH100125 to KEB). KEB has served as an advisory board member to Dainippon Sumitomo Pharmaceutical Neuralstem, and Takeda- Lundbeck. JN has received funding as an investigator from Assurex and from Janssen. JRK has received funds from Pathway Genomics as an investigator. All other authors have nothing to disclose. Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to American College of Neuropsychopharmacology.",
year = "2020",
month = sep,
day = "1",
doi = "10.1038/s41386-020-0683-2",
language = "English",
volume = "45",
pages = "1743--1749",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "10",
}
TY - JOUR
T1 - The association between lithium use and neurocognitive performance in patients with bipolar disorder
AU - Burdick, Katherine E.
AU - Millett, Caitlin E.
AU - Russo, Manuela
AU - Alda, Martin
AU - Alliey-Rodriguez, Ney
AU - Anand, Amit
AU - Balaraman, Yokesh
AU - Berrettini, Wade
AU - Bertram, Holli
AU - Calabrese, Joseph R.
AU - Calkin, Cynthia
AU - Conroy, Carla
AU - Coryell, William
AU - DeModena, Anna
AU - Feeder, Scott
AU - Fisher, Carrie
AU - Frazier, Nicole
AU - Frye, Mark
AU - Gao, Keming
AU - Garnham, Julie
AU - Gershon, Elliot S.
AU - Glazer, Kara
AU - Goes, Fernando S.
AU - Goto, Toyomi
AU - Harrington, Gloria J.
AU - Jakobsen, Petter
AU - Kamali, Masoud
AU - Kelly, Marisa
AU - Leckband, Susan
AU - Løberg, Else Marie
AU - Lohoff, Falk W.
AU - Maihofer, Adam X.
AU - McCarthy, Michael J.
AU - McInnis, Melvin
AU - Morken, Gunnar
AU - Nievergelt, Caroline M.
AU - Nurnberger, John
AU - Oedegaard, Ketil J.
AU - Ortiz, Abigail
AU - Ritchey, Megan
AU - Ryan, Kelly
AU - Schinagle, Martha
AU - Schwebel, Candice
AU - Shaw, Martha
AU - Shilling, Paul
AU - Slaney, Claire
AU - Stapp, Emma
AU - Tarwater, Bruce
AU - Zandi, Peter
AU - Kelsoe, John R.
N1 - Funding Information:
This work was supported by the US National Institutes of Mental Health and General Medical Sciences (MH92758 to JRK; MH100125 to KEB). KEB has served as an advisory board member to Dainippon Sumitomo Pharmaceutical Neuralstem, and Takeda- Lundbeck. JN has received funding as an investigator from Assurex and from Janssen. JRK has received funds from Pathway Genomics as an investigator. All other authors have nothing to disclose.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Lithium remains the gold standard for the treatment of bipolar disorder (BD); however, its use has declined over the years mainly due to the side effects and the subjective experience of cognitive numbness reported by patients. In the present study, we aim to methodically test the effects of lithium on neurocognitive functioning in the largest single cohort (n = 262) of BD patients reported to date by harnessing the power of a multi-site, ongoing clinical trial of lithium monotherapy. At the cross-sectional level, multivariate analysis of covariance (MANCOVA) was conducted to examine potential group differences across neurocognitive tests [California Verbal Learning Test (CVLT trials 1–5,CVLT delayed recall), Wechsler Digit Symbol, Trail-making Test parts A and B (TMT-A; TMT-B), and a global cognition index]. At the longitudinal level, on a subset of patients (n = 88) who achieved mood stabilization with lithium monotherapy, we explored the effect of lithium treatment across time on neurocognitive functioning. There were no differences at baseline between BD patients that were taking lithium compared with those that were not. At follow-up a significant neurocognitive improvement in the global cognitive index score [F = 31.69; p < 0.001], CVLT trials 1–5 [F = 29.81; p < 0.001], CVLT delayed recall [F = 15.27; p < 0.001], and TMT-B [F = 6.64, p = 0.012] was detected. The cross-sectional and longitudinal (on a subset of 88 patients) investigations suggest that lithium may be beneficial to neurocognitive functioning in patients with BD and that at the very least it does not seem to significantly impair cognition when used therapeutically.
AB - Lithium remains the gold standard for the treatment of bipolar disorder (BD); however, its use has declined over the years mainly due to the side effects and the subjective experience of cognitive numbness reported by patients. In the present study, we aim to methodically test the effects of lithium on neurocognitive functioning in the largest single cohort (n = 262) of BD patients reported to date by harnessing the power of a multi-site, ongoing clinical trial of lithium monotherapy. At the cross-sectional level, multivariate analysis of covariance (MANCOVA) was conducted to examine potential group differences across neurocognitive tests [California Verbal Learning Test (CVLT trials 1–5,CVLT delayed recall), Wechsler Digit Symbol, Trail-making Test parts A and B (TMT-A; TMT-B), and a global cognition index]. At the longitudinal level, on a subset of patients (n = 88) who achieved mood stabilization with lithium monotherapy, we explored the effect of lithium treatment across time on neurocognitive functioning. There were no differences at baseline between BD patients that were taking lithium compared with those that were not. At follow-up a significant neurocognitive improvement in the global cognitive index score [F = 31.69; p < 0.001], CVLT trials 1–5 [F = 29.81; p < 0.001], CVLT delayed recall [F = 15.27; p < 0.001], and TMT-B [F = 6.64, p = 0.012] was detected. The cross-sectional and longitudinal (on a subset of 88 patients) investigations suggest that lithium may be beneficial to neurocognitive functioning in patients with BD and that at the very least it does not seem to significantly impair cognition when used therapeutically.
UR - http://www.scopus.com/inward/record.url?scp=85083975541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083975541&partnerID=8YFLogxK
U2 - 10.1038/s41386-020-0683-2
DO - 10.1038/s41386-020-0683-2
M3 - Article
C2 - 32349118
AN - SCOPUS:85083975541
SN - 0893-133X
VL - 45
SP - 1743
EP - 1749
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 10
ER -
